VTGN vs. ACRV

Last updated Apr 1, 2026

Compare and contrast key facts about VistaGen Therapeutics, Inc. (VTGN) and Acrivon Therapeutics Inc. Common Stock (ACRV).

Performance

VTGN vs. ACRV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in VistaGen Therapeutics, Inc. (VTGN) and Acrivon Therapeutics Inc. Common Stock (ACRV). The values are adjusted to include any dividend payments, if applicable.

VTGN vs. ACRV - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
VTGN VistaGen Therapeutics, Inc.	-13.66%	-77.56%	-42.61%	66.34%	-35.26%
ACRV Acrivon Therapeutics Inc. Common Stock	-42.32%	-59.97%	22.36%	-57.29%	-30.77%

Fundamentals

Market Cap VTGN : $24.14M ACRV : $53.53M
EPS VTGN : -$1.83 ACRV : -$2.02
PB Ratio VTGN : 0.47 ACRV : 0.48
Total Revenue (TTM) VTGN : $790.00K ACRV : $0.00
Gross Profit (TTM) VTGN : $318.00K ACRV : $0.00
EBITDA (TTM) VTGN : -$68.03M ACRV : -$84.11M

Returns By Period

In the year-to-date period, VTGN achieves a -13.66% return, which is significantly higher than ACRV's -42.32% return.

VTGN

• 1D: 4.73%
• 1M: -2.47%
• YTD: -13.66%
• 6M: -83.90%
• 1Y: -77.14%
• 3Y*: -46.54%
• 5Y*: -61.28%
• 10Y*: —

ACRV

• 1D: 7.75%
• 1M: -7.95%
• YTD: -42.32%
• 6M: -23.20%
• 1Y: -31.53%
• 3Y*: -52.15%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

VTGN vs. ACRV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VTGN

VTGN Risk / Return Rank: 14
VTGN Sharpe Ratio Rank: 12
VTGN Sortino Ratio Rank: 22
VTGN Omega Ratio Rank: 19
VTGN Calmar Ratio Rank: 9
VTGN Martin Ratio Rank: 6

ACRV

ACRV Risk / Return Rank: 28
ACRV Sharpe Ratio Rank: 28
ACRV Sortino Ratio Rank: 36
ACRV Omega Ratio Rank: 35
ACRV Calmar Ratio Rank: 19
ACRV Martin Ratio Rank: 20

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VTGN vs. ACRV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for VistaGen Therapeutics, Inc. (VTGN) and Acrivon Therapeutics Inc. Common Stock (ACRV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	VTGN	ACRV	Difference
Sharpe ratio Return per unit of total volatility	-0.69	-0.29	-0.40
Sortino ratio Return per unit of downside risk	-0.37	0.27	-0.64
Omega ratio Gain probability vs. loss probability	0.93	1.03	-0.10
Calmar ratio Return relative to maximum drawdown	-0.87	-0.66	-0.20
Martin ratio Return relative to average drawdown	-1.65	-1.12	-0.53
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

VTGN vs. ACRV - Sharpe Ratio Comparison

The current VTGN Sharpe Ratio is -0.69, which is lower than the ACRV Sharpe Ratio of -0.29. The chart below compares the historical Sharpe Ratios of VTGN and ACRV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	VTGN	ACRV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.69	-0.29	-0.40
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.19	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.19	-0.50	+0.31

Correlation

The correlation between VTGN and ACRV is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

VTGN vs. ACRV - Dividend Comparison

Neither VTGN nor ACRV has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

VTGN vs. ACRV - Drawdown Comparison

The maximum VTGN drawdown since its inception was -99.76%, roughly equal to the maximum ACRV drawdown of -95.47%. Use the drawdown chart below to compare losses from any high point for VTGN and ACRV.

Drawdown Indicators

	VTGN	ACRV	Difference
Max Drawdown Largest peak-to-trough decline	-99.76%	-95.47%	-4.29%
Max Drawdown (1Y) Largest decline over 1 year	-89.69%	-57.14%	-32.55%
Max Drawdown (5Y) Largest decline over 5 years	-99.51%	—	—
Current Drawdown Current decline from peak	-99.73%	-94.01%	-5.72%
Average Drawdown Average peak-to-trough decline	-84.16%	-69.27%	-14.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	47.24%	33.81%	+13.43%

Volatility

VTGN vs. ACRV - Volatility Comparison

The current volatility for VistaGen Therapeutics, Inc. (VTGN) is 16.09%, while Acrivon Therapeutics Inc. Common Stock (ACRV) has a volatility of 19.87%. This indicates that VTGN experiences smaller price fluctuations and is considered to be less risky than ACRV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	VTGN	ACRV	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.09%	19.87%	-3.78%
Volatility (6M) Calculated over the trailing 6-month period	172.34%	75.44%	+96.90%
Volatility (1Y) Calculated over the trailing 1-year period	111.79%	108.07%	+3.72%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	320.27%	105.27%	+215.00%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	241.30%	105.27%	+136.03%

Financials